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Abstract:  Retroviruses are well known pathogens of mammals, birds and fish. Their 
potential to induce cancer in chickens was already described almost 100 years ago and 
murine retroviruses have been a subject of study for 50 years. The first human retroviruses, 
HTLV and HIV, were discovered more than  30 years ago, surprising researchers and 
physicians by the profound differences in the diseases they cause. HTLV-1 is able to 
induce, after decades of infection, lymphomas/leukemia or neuroimmune disorders 
whereas untreated HIV infection leads almost inevitably to AIDS. The recently described 
XMRV (xenotropic murine leukemia virus-related virus) appeared to possess many of the 
features known for HTLV and was regarded by some to be the third human retrovirus. 
However, recent publications by Knox et al. [1] and Paprotka et al. [2] have shed new light 
on this gammaretrovirus. Knox and colleagues clearly demonstrate that XMRV is absent in 
patients belonging to a chronic fatigue syndrome cohort who had previously been reported 
to be XMRV-positive  [3]. This supports the growing suspicion that laboratory 
contamination was responsible for the postulated link between XMRV and the disease. 
Furthermore, Paprotka et al’s  identification of XMRV’s origin and the phylogenetic 
analysis of known XMRV  sequences are further nails in the coffin to the notion that 
XMRV is a clinically relevant infectious human retrovirus. 
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1. XMRV: A New Human Retrovirus? 
XMRV  (xenotropic murine leukemia virus-related virus)  was first reported as a potential new 
retrovirus of humans in 2006 [4] when a microarray approach revealed its presence predominantly in 
tissues from patients with familial prostate cancer who were also homozygous for a mutation (R462Q) 
in the gene for RNASE L, an enzyme involved in innate antiviral immunity. Interestingly, XMRV was 
initially reported to be present exclusively in stroma cells but not in the tumor cells themselves, a 
finding that appeared to exclude a common mechanism of malignant transformation by 
gammaretroviruses. The presence of XMRV in prostate cancer patients was later confirmed by others 
[5-7], although the virus was usually found in tumor cells and with no correlation to the RNASE L 
genotype. In sharp contrast, many studies found a much lower prevalence or even complete absence of 
XMRV [8-14]. One critical result in 2009 seemed to support the link between XMRV and prostate 
cancer by discovering the virus in the primary prostate carcinoma-derived cell line 22Rv1 [15].  
2. XMRV and Chronic Fatigue Syndrome 
In 2009, attention became more intensely focused on XMRV when Judy Mikovits’ group at the 
Whittemore Peterson Institute in Reno, Nevada, reported in Science  that 67% of chronic fatigue 
syndrome (CFS) patients were XMRV positive [3] and that the virus was also present in the blood of 
3.7% of healthy controls. The study used multiple lines of evidence (PCR, virus isolation and detection 
of specific antibodies) to demonstrate XMRV sequences and proteins in peripheral blood mononuclear 
cells (PBMC) and the presence of cell-free transmittable virus in patients’ plasma.  
This study was immediately challenged by other reports, initially from Europe [16-18] and later 
from the US [19-22] that could not confirm the findings. The potential association between a new 
pathogen and CFS and the implied spread of a previously unrecognized gammaretrovirus in humans 
were nevertheless of great concern. Despite all warnings that the link between CFS and XMRV could 
not be confirmed, many patients suffering from this debilitating disease and desperately hoping for a 
cure started taking anti-retroviral drugs. However, the increasing number of reports failing to find a 
retroviral etiology for CFS and other disorders [23-26] cast further doubt on the reliability of the 
original findings. The authors and enthusiasts of the original CFS study [3] attempted to dismiss such 
negative results on the grounds of inadequate diagnostic procedures or inappropriate selection of 
patients  [27], demanding that the methods used in the original paper be meticulously replicated. 
However, a recent study [28] again found no evidence for XMRV despite using virtually identical 
PCR, serology and virus isolation methodologies to investigate samples from some of the same CFS 
patients found to be positive in the initial study [3].  
The prevalence of XMRV in CFS patients was also addressed by Knox and colleagues [1] who 
investigated a total of 61 CFS patients of which 43 had previously been found to be XMRV-positive 
by a commercial (VIPDx, Reno, NV, USA) or research laboratory (Whittemore Peterson Institute, 
Reno, NV, USA) using the methodology of Lombardi et al. [3]. Duplicate blood samples drawn on the 
same day by the same phlebotomist were available for 19 of these patients and, remarkably, in 10/19 
cases samples tested positive for XMRV DNA by VIPDx while 0/19 tested positive by Knox et al. [1]. 
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different tests: PCR and RT-PCR on nucleic acids from stimulated or unstimulated PBMC, RT-PCR 
for the detection of viral RNA in the plasma and even incubation of susceptible mink lung cells with 
patients’ plasma or PBMC culture supernatants to facilitate enhanced detection of infectious virus 
particles. Despite 26 of these 29 CFS patients having been previously tested positive by VIPDx or the 
Whittemore Peterson Institute  using one or more of these methods,  no trace of XMRV could   
be detected.  Furthermore, when Knox  et al.  investigated 60 plasma samples for the presence of   
XMRV-specific antibodies using an established chemiluminescence immunoassay [1], just one was 
weakly reactive for XMRV gp70  and the specificity  of this reaction could not be confirmed by 
Western blot.  
3. The Origin of XMRV  
Paprotka and colleagues [2] decided to track down the origin of XMRV. As mentioned above, the 
prostate cancer cell line 22Rv1 contains over 10 proviral XMRV copies/cell [15]. This cell line was 
developed by the serial passage of a human prostate xenograft (CWR22) in nude mice from 1992 to 
1999 and it was therefore important to know whether the virus was already present in the patient who 
provided the xenograft or if XMRV infection of the human cells occurred during passaging in mice.  
Paprotka and colleagues therefore characterized XMRV infection in early and late passages of the 
prostate cancer xenograft that eventually gave rise to the cell lines 22Rv1 and CWR-R1. They found 
no evidence for 'human' XMRV in early passages of the tumor xenograft but found instead two 
XMRV-related proviruses with complementary regions of high homology to prototypic XMRV, 
sequences that they named preXMRV-1 and preXMRV-2. However, later passages of the xenograft 
and both resulting cell lines contained the XMRV prototype sequence closely matching that reported in 
humans (Figure 1). This clearly demonstrates that the virus was not present in the original human 
tumor but was acquired later.  
What, then, was the source of preXMRV-1 and preXMRV-2 in the xenografts and where did 
‘human’ XMRV form? By the time of testing, the xenografts had presumably become infiltrated with 
murine cells and the preXMRV-1 and preXMRV-2 proviruses were therefore amplified from traces of 
genomic murine DNA in the xenograft samples. This was confirmed by analyzing tissues from the 
strains of nude mice likely to have been used in the 1992-1999 xenograft experiments. The 
complementary XMRV precursor proviruses (preXMRV-1 and -2) were indeed found in two of these 
strains (but no 'human' XMRV) and the authors therefore concluded that in the mid-1990s 
recombination between the two parental MLVs in a xenografted nude mouse gave birth to XMRV. 
While the replication-defective preXMRV-1 is closely related to xenotropic endogenous MLV,   
pre-XMRV-2 resembles the polytropic or modified-polytropic type. The fact that preXMRV-1 
(xenotropic) contributed the envelope protein to ‘human’ XMRV might explain why the new virus 
could replicate in the human xenograft but not in the murine host itself. Comparing the sequences of 
preXMRV-1 and preXMRV-2 with that of XMRV, the authors suggest that a virus particle containing 
both preXMRV-1 and preXMRV-2 genomic RNA must have formed. This particle then infected a cell 
and six reverse transcriptase template switching events during minus-strand DNA synthesis resulted in 
the mosaic sequence known as XMRV (Figure 2). This scenario is completely plausible as it is known 
that the RNAs of two related proviruses can occasionally be incorporated into a single virion and  Viruses 2011, 3                                       
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that reverse transcriptase usually switches between the two RNA templates an average of four times 
per cycle [29].  
Figure 1.  Generation of XMRV during passage of the CWR22 xenograft  [2]. Human 
prostate cancer tissue was xenografted into nude mice (that carry both endogenous 
proviruses parental to XMRV) in 1992. Due to the presence of varying traces of murine 
cells, all xenografts and the CWR-R1 cells were positive for preXMRV-1 and in some 
cases also for preXMRV-2. XMRV is only present in late xenografts generated after 1996 
and in both of the derived cell lines. (Nude mouse picture by A. Kübelbeck [30]). 
 
Figure 2.  Recombinant origin of the XMRV sequence  [2]. The preXMRV-1 and 
preXMRV-2 genomes with their homology to the XMRV consensus sequence are shown. 
Template switching events indicated with blue arrows occurred in regions of 20-73 
nucleotide identity between both viral RNAs. Nucleotide numbers refer to 22Rv1 XMRV 
(Acc. No. FN692043). Six template switching events result in a sequence differing from all 
known XMRV isolates by only 4-13 nucleotides. 
 
Paprotka  et al. calculated that the likelihood of precisely this recombination pattern occurring 
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1.3 × 10
−12. As every XMRV sequence published to date has the same six predicted recombination 
sites, it is clear that they all originate from this unique recombination event during the establishment of 
the 22Rv1 cell line. Indeed, the possibility of XMRV having a recombinant origin had already been 
suggested [31]. XMRV itself appears to be completely absent in mice: none of the 45 laboratory and 
44 feral mouse strains tested by the authors harbored the complete provirus. However, some have one 
or other of the parental precursor viruses and both are found simultaneously in just two strains (those 
used for passage of the original xenograft). This general lack of XMRV in mice virtually rules out the 
possibility that mice have passed the virus onto humans.  
4. Concluding Remarks 
Although rhesus monkeys can be infected with very high amounts of XMRV [32], there is 
substantial evidence that the virus does not easily infect, replicate and circulate in humans. The first 
indication is that XMRV, like other xenotropic MLVs, is subject to a severe restriction of replication in 
primary human cells through the activity of antiviral factors such as APOBEC3 and tetherin [33-35]. 
These protective proteins inhibit efficient replication in human PBMC and most likely in other primary 
human cells. We and others have demonstrated that PBMC have a low susceptibility to XMRV 
infection and, if infected, release very low levels of infectious virus [26,36].  
Furthermore, Knox and colleagues [1]  showed that XMRV and other xenotropic MLVs are 
inactivated by sera from both healthy donors and CFS patients, probably by the action of human 
complement. Finally, many groups, including that of Knox et al, have demonstrated the high 
probability of false-positive PCR results being the reason for the earlier reports linking XMRV to 
disease [1,20,28,37,38]. Contamination of patient samples, cells in culture or lab reagents with murine 
DNA, plasmid DNA containing XMRV sequences or even the virus itself [39] can easily occur if 
stringent precautions are not taken. Finally, the lack of variation between sequences supposedly 
obtained from different individuals [1,40] argues against the presence of XMRV in humans as this is 
not consistent with our current knowledge of retrovirus replication and spread. 
In summary, taking all data and the many negative studies into account, there is little to support the 
idea that XMRV is a retrovirus infecting humans and that it has clinical relevance for prostate cancer 
or CFS. It transpires that XMRV is not a new human tumor virus after all, but rather the latest example 
of a “rumor” virus [41].  
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